Profile
Theo H.
Walthie is currently a Member-Supervisory Board at LANXESS Deutschland GmbH.
Previously, he served as Chairman at NBE-Therapeutics AG.
He also held the position of Global Business President-Hydrocarbons & Energy at The Dow Chemical Co. from 1970 to 2007.
Additionally, he was a Member-Supervisory Board at Lanxess AG from 2010 to 2022.
Mr. Walthie obtained his undergraduate degree from Delft University of Technology.
Theo H. Walthie active positions
| Companies | Position | Start |
|---|---|---|
LANXESS Deutschland GmbH
LANXESS Deutschland GmbH Chemicals: SpecialtyProcess Industries Produces and sells chemicals | Director/Board Member | - |
Former positions of Theo H. Walthie
| Companies | Position | End |
|---|---|---|
| LANXESS AG | Director/Board Member | 25/05/2022 |
NBE-Therapeutics AG
NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Chairman | 10/08/2020 |
| DOW CHEMICAL COMPANY (THE) | Corporate Officer/Principal | 01/01/2007 |
Training of Theo H. Walthie
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
The Dow Chemical Co.
The Dow Chemical Co. Chemicals: Major DiversifiedProcess Industries Manufactures specialty additives, modifiers and plastic polyethylene products | Process Industries |
LANXESS AG
LANXESS AG Chemicals: Major DiversifiedProcess Industries Produces and sells specialty additives, intermediaries and engineering materials | Process Industries |
Delft University of Technology
Delft University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LANXESS Deutschland GmbH
LANXESS Deutschland GmbH Chemicals: SpecialtyProcess Industries Produces and sells chemicals | Process Industries |
NBE-Therapeutics AG
NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Health Technology |
- Stock Market
- Insiders
- Theo H. Walthie
















